BLEPH-30
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BLEPH-30 (BLEPH-30).
BLEPH-30 is a topical formulation containing 30% sulfacetamide sodium, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, interfering with folic acid synthesis and exerting bacteriostatic activity against susceptible organisms.
| Metabolism | Sulfacetamide undergoes hepatic metabolism via acetylation and hydroxylation, with minor renal excretion of unchanged drug. |
| Excretion | Primarily renal excretion of unchanged drug, accounting for approximately 90% of elimination; minor biliary/fecal route (<10%). |
| Half-life | Terminal elimination half-life is approximately 2.5 hours in adults with normal renal function; clinically, dosing intervals may need adjustment in renal impairment. |
| Protein binding | Approximately 30–40% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution (Vd) is 0.3–0.5 L/kg, suggesting distribution primarily into extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 95% due to extensive gastrointestinal absorption. |
| Onset of Action | Oral administration: onset within 30–60 minutes. |
| Duration of Action | Duration of action is 4–6 hours for oral formulation; clinical effect correlates with serum concentrations above minimum inhibitory concentration. |
| Molecular Weight | 129.2 |
One drop to the affected eye(s) every 12 hours. Not to exceed 2 drops per eye per day.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No renal dose adjustment required for ophthalmic use. |
| Liver impairment | No hepatic dose adjustment required for ophthalmic use. |
| Pediatric use | Not recommended in children under 2 years. For ages ≥2 years, same as adult dosing. |
| Geriatric use | Same as adult dosing. Monitor for ocular adverse effects. |
| 1st trimester | No adequate studies in pregnant women. Use only if clearly needed. |
| 2nd trimester | No adequate studies in pregnant women. Use only if clearly needed. |
| 3rd trimester | No adequate studies in pregnant women. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for BLEPH-30 (BLEPH-30).
| Placental transfer | Unknown; molecular weight suggests minimal transfer if any. |
| Breastfeeding | Not known if blepharospasm treatment has systemic absorption sufficient to enter breast milk. Caution advised. |
| Lactation Rating | L3 |
■ FDA Black Box Warning
Sulfonamides have been associated with severe reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and agranulocytosis. Fatalities have occurred. Discontinue at first sign of rash or any sign of hypersensitivity.
| Serious Effects |
Hypersensitivity to any componentMyasthenia gravisEaton-Lambert syndrome
| Precautions | Hypersensitivity reactions: Rash, fever, joint pain, and anaphylaxis may occur., Ocular irritation and stinging upon application., Prolonged use may lead to overgrowth of non-susceptible organisms, including fungi., Avoid use in patients with known sulfonamide allergy. |
| Food/Dietary | No significant food interactions known. Avoid alcohol as it may exacerbate ocular irritation. |
Loading safety data…
| Teratogenic Risk | BLEPH-30 is a fixed-dose combination of brimonidine and timolol. Brimonidine is pregnancy category B with no evidence of teratogenicity in animal studies; timolol is pregnancy category C, associated with fetal bradycardia and growth restriction in animal studies. First trimester: Risk cannot be excluded, but systemic absorption is low with ophthalmic use. Second and third trimesters: Beta-blocker effect may cause fetal bradycardia, hypotension, and hypoglycemia; avoid use if possible. |
| Fetal Monitoring | Monitor maternal heart rate and blood pressure. In pregnancy, consider fetal heart rate monitoring and ultrasound for growth if used chronically. Observe neonate for bradycardia, respiratory depression, and hypoglycemia if used near term. |
| Fertility Effects | No adverse effects on fertility reported in animal studies for either component. No human data available. |
| Clinical Pearls | BLEPH-30 (blephamide ophthalmic suspension 10% sulfacetamide/0.2% prednisolone acetate) is a steroid-antibiotic combination used for steroid-responsive inflammatory blepharoconjunctivitis. Shake vigorously before each use. Do not use in patients with dendritic keratitis (herpes simplex) or fungal infections. Monitor intraocular pressure if used >10 days. Discard after 30 days of opening. |
| Patient Advice | Shake the bottle well before each use. · Do not touch the dropper tip to any surface to avoid contamination. · Remove contact lenses before instillation; wait at least 15 minutes before reinserting. · Temporary blurred vision may occur; wait until clear before driving. · Complete the full course even if symptoms improve; do not stop abruptly. · Report worsening redness, pain, or vision changes to your healthcare provider. |